Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DETROIT H.T.C.C. EXPECTING TO BE A RECORD CROWD-
DETROIT - The High Times Cannabis Cup is coming to Detroit this weekend.
The event will be held Saturday and Sunday at the Russell Industrial Center in Detroit. People 21 years old or older can attend the event. Those who are 18 to 20 years old may enter if they have a medical marijuana card.
Multiple performers are expected at the event including the Wu-Tang Clan, 2 Chainz, Warren G, Trick Trick, Willy J Peso, We Are Culture Creators and Kid Vishis.
"High Times is bringing all the action we brought to the Auto City Speedway and more to the Paris of the Midwest! Featuring an even bigger lineup, more booths, and oh yeah, LEGAL CANNABIS - this one’s going to go down in the record books," was shared on the Facebook event.
guys, i'm sure PAOG will have a very successful-
time this weekend at the DETROIT HIGH TIMES CANNIBIS CUP-
BUT -THE BIG ISSUE, many here seem to be ignoring, is the fact that the
FDA is about to make a historical change on its stance CBD . when this happens, it will open up the floodgates for millions of new investors to
pour into CBD stocks. it will be an unprecedented MANIA like we have never before seen .
the FDA changing its stance on CBD-
will have HISTORIC,MONUMENTAL AFFECT ON companies like PAOG-
and will start a CBD MANIA NEVER BEFORE SEEN !!!
Top FDA Official Slams Federal Drug Scheduling System For Blocking CBD Research
Published 1 day ago on August 13, 2019
By Kyle Jaeger
The federal drug scheduling system inhibited research into CBD that the Food and Drug Administration (FDA) is now scrambling to conduct following the legalization of hemp and its derivatives, a top agency official said on Tuesday.
Speaking at the National Industrial Hemp Council’s 2019 Hemp Business Summit, FDA Principal Associate Commissioner for Policy Lowell Schiller gave an extensive overview of the agency’s role in regulating cannabis products, repeatedly stressing that FDA is “excited” about cannabidiol’s potential.
That said, Schiller said FDA retains regulatory authority over hemp-derived products and it remains illegal to introduce CBD in the food supply or as dietary supplements unless the agency develops alternative rules, which it is actively exploring. Because CBD exists as an FDA-approved epilepsy drug, Epidiolex, creating a regulatory framework is more complicated.
He also talked about other potential medical benefits of CBD and how the federal ban on hemp and its compounds, which was lifted under a provision of the 2018 Farm Bill that President Donald Trump signed in December, restricted research.
“There’s still a lot we don’t know about the potential therapeutic benefits of CBD, but we’re excited about the possibility that new therapeutic uses of CBD might be demonstrated to be safe and effective,” Schiller said, according to his remarks as prepared for delivery. “The last thing we want to do is to discourage that research, and potentially stunt our knowledge of potential uses of CBD. So we need to be thoughtful in our approach.”
“One thing we realized very early on in evaluating these questions is that there was still far too much we didn’t know about CBD, and about the implications of putting CBD in foods, dietary supplements, and cosmetics,” he said. “This is part of the legacy of almost all CBD being a Schedule I controlled substance until late last year.”
“It was difficult to research, and it hasn’t been studied nearly as much as we would like.”
Schiller said that more studies are needed to determine potential risks associated with consuming large quantities of CBD, interactions with other drugs, using the substance while pregnant and long-term consumption. Resolving those questions will “help to inform our path forward.”
That’s why, he said, FDA is “focusing on a different CBD: Collect Better Data.”
“We want to learn as much as we can, as quickly as we can, to support informed and efficient decision making. If there are data or studies that are relevant to the safety of particular uses of CBD, we want to see them. And if there are gaps in our knowledge, we want to understand how big those gaps are and what can be done—by us and by others—to start filling them.”
Those gaps in knowledge are partially due to the federal drug scheduling system, which has faced bipartisan criticism for hampering research initiatives. The director of the National Institute on Drug Abuse acknowledged in April that continuing to classify drugs like marijuana as Schedule I makes it “very difficult” to research.
But as FDA works to make up for lost time, it has pledged to engage in a transparent rulemaking process that takes into account what Congress and industry stakeholders have called for—namely a regulatory scheme under which hemp and CBD can be lawfully marketed without excessive interference.
FDA said it is speeding up its process to develop regulations and that it plans to release a report on its progress in the fall.
“In closing, I want to reiterate how excited we are about the potential uses of CBD and other hemp and hemp-derived products,” Schiller said. “The hemp industry has come an incredible distance in an incredibly short period of time. And in some cases, the enthusiasm and the commercial appeal have outpaced the scientific research. The science needs to catch up.”
He also told the hemp crowd that as FDA works on its end, “we need your help.”
“As this industry matures, it needs to start taking on more responsibilities—for the safety of consumers, and for the future development of an industry that can meet the same requirements as apply to other industries we regulate,” he said. “We look forward to working together as this industry continues to mature.”
this we do know-
KARL RIEDEL definitely has the connections , with OVER 9,000 affiliates
with his last company. let's see where he takes this company.
pressure is on the FDA to make-
a decision soon on CBD. the implications could be a major boon for
companies like PAOG. the clock is ticking for a new "CBD MANIA" to start.
THIS WILL BE HUGE FOR PAOG-
CBD-Laced Foods Could Be Technically Illegal, But the FDA Might Soon Change That
Agency has the authority to carve out an exception to existing laws.
By DEBRA BORCHARDT Aug 13, 2019 | 11:00 AM EDT
Is CBD -- a compound in marijuana that allegedly makes you feel good but isn't the chemical that actually makes you high -- a drug or a food supplement? The legal-marijuana industry has been waiting for the U.S. Food and Drug Administration to rule on that question, but one analyst thinks it can be both.
Legal-pot companies and food manufacturers have begun adding cannabidiol (or "CBD" for short) to all sorts of beverages and other items as a "feel-good" substance. But whether they can continue to do so will depend on whether the FDA rules that the substance is a dietary supplement or a drug.
Bank of America cannabis analyst Christopher Carey thinks the FDA will decide CBD is both, based on two laws.
The first is the 2018 farm bill, under which Congress legalized hemp (non-psychoactive marijuana used for rope), but left it to the FDA to work out the logistics. The second law is the Dietary Supplement Health and Education Act of 1994 (DSHEA), which defined dietary supplements as a new class of food.
The 1994 law deals in part with how to handle substances that have been as both prescription drugs and as food supplements. For companies to market a substance as a food supplement, it must have been sold as such before a pharmaceutical company launched drug trials designed to use the material as a prescription drug.
Given that GW Pharmaceuticals (GWPH) has created a drug called Epidiolex out of CBD to treat two forms of epilepsy, does that mean companies can't use CBD as a food supplement?
"Many in the CBD industry argue CBD was marketed prior to trials (e.g. Epidiolex)," Bank of America's Carey wrote in a recent note. "In our view, while a potentially valid argument, CBD has been illegal for decades, making this approach complicated."
Certainly hemp products have been sold in various food markets for years, but CBD as a wellness dietary supplement is new. Plus, cannabis was sold by major drug companies at the turn of the 19th century before prescriptions were needed.
That further muddies the argument. If CBD didn't need a prescription then, does that mean it was a food supplement or not?
This all came into sharp focus recently when the FDA sent a warning letter to popular cannabis company Curaleaf Holdings (CURLF) complaining that the company was making unproven medicinal claims about its CBD-infused products. That caused CURLF's stock to briefly fall and prompted Curaleaf's new retail partner CVS Health (CVS) to yank the products in question off of its shelves.
Curaleaf quickly responded by removing marketing language that the FDA had objected to. "Our industry needs, wants and appreciates the work the FDA is doing to ensure there is regulation and compliance in the CBD marketplace," CEO Joseph Lusardi wrote the agency. Still, the FDA's objections spawned numerous shareholder lawsuits against Curaleaf.
Michael Harinen, chief brand officer at CBD-products company Bluebird Botanicals, said the FDA could help the industry by making it a "first step ... to formally say that they will practice enforcement discretion in the CBD industry. This means they may hold off on enforcing any existing restrictions or impeding operations for CBD companies so long as the companies are not violating DSHEA by making health claims."
He said the agency could then say that it "will likely be more serious about going after the companies that are making health claims -- and possibly even those using structure/function claims."
Making an Exception
Carey believes that the FDA will try to find a way for CBD to coexist as both a supplement and as a prescription drug like Epidiolex.
He points out that the FDA has some wiggle room to make an exception, noting that the agency recently wrote that "the statutory provisions that currently prohibit marketing CBD in these forms also allow the FDA to issue a regulation creating an exception."
The analyst wrote that while he thinks products with "highly refined CBD ... will be viewed too similar [to] Epidiolex, other forms of CBD could be allowed."
In other words, if a CBD product looks too much like GW Pharmaceuticals' prescription drug, then it won't be allowed. But if a CBD product is on a much lower level of refinement, then it'll be OK.
Prior Cases
The analyst suggested that investors look at how the FDA treated a product called Cholestin, which was made from red rice yeast by a company called Pharmanex and designed to promote healthy cholesterol.
Cholestin contained a natural substance called "mevinolin," which is chemically identical to lovastatin - the active ingredient in a prescription drug called Mevacor. The FDA blocked Pharmanex's plan in 1997 to sell Cholestin, arguing that the company refined its red rice yeast and marketed its product to pharmacists -- pushing it beyond a dietary supplement.
Carey also cited the 2009 case of pyridoxamine supplements, which are a form of Vitamin B6. Pharmaceuticals company Biostratum makes a prescription drug called Pyridorin that uses pyridoxamine dihydrochloride as its active ingredient. As a result, the FDA ruled that pyridoxamine can't be sold as a dietary supplement.
Both of the cases above ended badly for the dietary-supplement products, but Carey thinks CBD will be different.
However, Bluebird Botanicals' Harinen says it's hard to predict when the FDA will make a decision on the substance's status. "This process can take anywhere from two to three years," he said. Still, Bluebird and many other companies in the hemp space have joined together in encouraging the FDA to expedite the process.
Former FDA Commissioner Scott Gottlieb even recently wrote in a Washington Post opinion piece that the FDA should speed up the process.
The FDA "can approve the sale of some CBD products immediately, while effecting a framework for their safe and proper regulation and a pathway for an enforceable market for these goods," Gottlieb wrote. "The [agency] could put the onus on manufacturers to bring forward petitions to demonstrate that CBD can be safely added to products such as food."
SEPTEMBER WILL BE HUGE FOR PAOG $$$$$$$
that will be the start of "CBD MANIA", and PAOG
is primed and poised to take full advantage of this once in a lifetime
opportunity. do you guys remember SEPTEMBER 2016- many OTC/BB MJ STOCKS
went PARABOLIC-with many going UP 1000 %%%%%%%%%%
“It’s particularly thrilling to take part in this record-breaking event right here in our backyard of the Midwest,” continued Mr. Riedel.
GO PAOG $$$$$$$
PAOG Hosts Meet-and-Greet Booth at HIGH TIMES Cannabis Cup in Detroit, MI, August 17-18. Launch of HIGH END Products Brand and CBD Only
SANDUSKY, OH / ACCESSWIRE / / PAO Group, Inc. (OTC Pink: PAOG) (“PAO Group” or the “Company”) is pleased to announce that it will host a “Meet-and-Greet” vendors booth at the HIGH TIMES Cannabis Cup in Detroit, Michigan. The Detroit Cannabis Cup will be held at the Russell Industrial Center on August 17-18, 2019. PAOG will launch its premium HIGH END Products™ cannabis brand and debut a newly produced CBD-only variant of its flagship product Cannophen™ during the event. The Company wishes to extend a warm invitation to shareholders and customers to come and meet the PAOG team at the Detroit Cannabis Cup.
“We are thrilled to participate in such an apex event for the cannabis industry,” said Karl Riedel, CEO of PAOG. “I executed our contract with HIGH TIMES and we are now an official vendor with a booth to debut our new products, as well as submitting four entries in the Detroit Cannabis Cup competition! The Cannabis Cup gives PAOG broad exposure before our core customer base, recognition before industry luminaries, and connection to vital distribution channels. We are seizing this golden opportunity to officially launch our scientifically formulated HIGH END Products™ brand. We are debuting our C-CUP™ 510 Vape Cartridges, which feature cutting-edge vapor technology, including a unique ceramic dual-heating element reservoir "cup" to deliver maximum flavor and vapor. Our precision distillation processes ensure that customers receive the highest potency, consistency, and quality in all of our THC and CBD products. The proof is in their performance. Results from initial consumer tests have been extremely positive and we are confident our new products can compete toe-to-toe with anything offered in the cannabis sector. We are very proud to be entering four of our premium mainstay products into the Detroit Cannabis Cup competition:
HIGH END Products™ C-CUP™ 510 Vape Cartridges - Premium THC Distillate - “Pink Mimosa” (Straw-Nana X Mimosa)
HIGH END Products™ Full-Spectrum CBD Distillate
Cannophen™ THC/CBD Premium Blend Capsules
Cannophen™ Broad-Spectrum CBD Capsules
Of special note is PAOG’s Cannophen™ Broad-Spectrum CBD (now available in capsules, and coming soon in vape cartridges). The Cannophen™ CBD-only variant just completed a pilot production run and the Detroit Cup will be the maiden debut for industry insiders and consumers alike. This is a new variant of the THC/CBD Cannophen™ capsules the Company launched in June of this year, but as a CBD-only product, it creates wider distribution opportunities for PAOG. The new Cannophen™ Borad-Spectrum CBD products can be distributed internationally, via online channels, and as a product targeting a health and wellness market that overlaps and reaches beyond THC product customers. Cannophen™ Broad-Spectrum CBD Capsules feature 25mg of CBD distillate engineered to be rapidly bioactivated by the body’s metabolism via an alternate rapid delivery system. Our CBD distillate is sourced from high-CBD industrial hemp that is precisely cared for, without any pesticides. Refined using state of the art molecular distillation technology, this is our most potent CBD distillate, containing 80%+ CBD while retaining terpenes and other beneficial cannabinoids, without the chlorophyll and other heavier components that affect color and flavor. CBD is a non-psychoactive derivative of hemp. Mounting research points to a myriad of health benefits offered by CBD, including relief from anxiety, inflammation, and addictions. The global CBD market has been expanding at an unprecedented rate, and is expected to grow to over $20 billion by 2022.
“It’s particularly thrilling to take part in this record-breaking event right here in our backyard of the Midwest,” continued Mr. Riedel. “The sold-out attendance of the last Cup demonstrates that demand in this region is greater than ever and shows no sign of slowing down. We are pleased to extend an invitation to all those who have followed the Company over the years: come out to the Detroit Cannabis Cup and get to know the PAOG team! We want to get your feedback, hear your thoughts and concerns, answer your questions and listen to your ideas for new products in the future. Your input is invaluable to us. We see this as an opportunity to give back to our loyal base. Our booth will feature a ‘Roaring Twenties’ theme. We’ve hired models to dress as 1920’s ‘Flappers’ and plan to have a vintage Ford Model A automobile on display.This is likely to be the largest industry event in our region this year by far, and we want to make this time with our base a truly memorable experience. It’s an opportunity for tens of thousands of our core demographic to become familiar with our HIGH END Products™ brand and Cannophen™ products, and to take their great first impressions viral amongst their respective networks. We are pulling out all the stops to make the most of that opportunity! Come out and try our HIGH END Products™ line - we are confident you will love it.”
Leading industry experts recognize the HIGH TIMES Cannabis Cup as the premier cannabis trade show worldwide. The Company attended the previous Cannabis Cup in Clio, Michigan on June 8-9 of this year. The event sold out both days, drew a record estimated 50,000 attendees and featured over 260 vendors. It is due to this unprecedented demand that HIGH TIMES scheduled a second Cannabis Cup in Michigan this year. The Detroit Cup will feature a higher capacity venue, a larger lineup of musical headliners including Wu-Tang Clan, 2 Chainz, and Warren G, and is expected to attract more vendors than the Clio, MI event. The Detroit Cannabis Cup is expected to sell out so attendees are encouraged to get their tickets early.
'High Times Cannabis Cup' coming to Detroit this weekend - WXYZ.com
DETROIT (WXYZ) — It's been more than eight months since marijuana became legal in Michigan, and a huge marijuana-themed event is headed to Detroit this weekend.
The High Times Cannabis Cup will take place on Saturday and Sunday at the Russell Industrial Center. It's sponsored by High Times magazine, the first month publication that advocated for marijuana legalization back in 1974.
This is the second time in three months it has come to Michigan. The two-day marijuana festival was held in June at Auto City Speedway just north of Flint in Clio.
Performers for the show include 2 Chainz, Wu-Tang-Clan, Warren G, Detroit's own Trick Trick and more.
If you want to attend the event, you must be 18-20 years old with a valid ID and medical card, but you don't need a medical card if you are 21 and up.
Tickets for the show start at $40 for one-day general admission and $90 for 2-day general admission.
For more information, click here .
"CBD POPULARITY IS AT ALL-TIME HIGH "-
KARL RIEDEL knows what he has here.
tick..tick..tick………..
Online Searches for CBD Officially Surpass Beyoncé and Kim Kardashian
By Gabriela Barkho • 08/04/19 10:30am
Web and social media search for CBD is at an all time high.
CBD is officially more popular than Beyoncé. At least when it comes to internet research.
According to CannabisMD’s Knowledge Navigator, a backend tool used to survey consumer trends, online interest in cannabidiol, more popularly known as CBD, has spiked exponentially in the past year. The data analyzed was pulled from a wide array of user searches across the web, including over 12,000 URLs, along with social media platforms like Instagram and Twitter.
SEE ALSO: The Process to Regulate CBD Will Speed Up, According to the FDA
As the Navigator-generated chart shows, the number of searches entered for CBD have consistently risen since 2017, with no peak in sight. As of 2019, the tool’s graphs show CBD’s popularity has surpassed several popular topics, including Beyoncé, Kim Kardashian, kale and veganism.
Search for CBD appears to surpass megastar Beyoncé sometime in mid-2018. cMD Knowledge Navigator and Google Historical Data
For context, the Knowledge Navigator’s data is in line with current Google search trends, which show a similar historical uptick for the term “CBD.” The timing of the intense interest in cannabidiol taking off in 2018 makes sense; last year was when hemp saw a national decriminalization that helped get CBD production off the ground.
Countless startups currently sell cannabidiol-infused products for wellness purposes, with benefit claims ranging from reducing anxiety to curing seizures. In fact, the marketing for many CBD-containing products has come under fire in recent months, with an increase in calls for industry regulation.
It’s clear that consumer interest is at an all time high, as the search data shows, and is expected to continue growing upward at this rate. After all, with the number of CBD producers increasing at an incredible rate—the market is set to reach $20 billion by 2424—consumer fascination with CBD is likely to continue trending up too.
"CBD MANIA" -
is COMING !!!
( from the "GREAT SLEEK" )
Why This Cannabis Sector Will Outshine All Others in 2019
The past year has seen an unprecedented FDA approval, the nationwide legalization of recreational cannabis in Canada, and multiple states taking measures to reform prohibition. But this year, one sector alone will trump all of that.
Last year was monumental for cannabis.
To kick off the year, California, with a population of nearly 40 million people, began sales of fully legalized marijuana for recreational use.
Over the summer, the FDA approved the use of a cannabis-derived drug for the first time then, in the fall, the roll-back of cannabis prohibition hit the national-scale in Canada. All the while, states took it upon themselves to extend the legalization of cannabis, whether for medical or recreational use, across the United States.
And just last month, the cultivation and sale of a type of cannabis plant – hemp – and products derived from it became legal across the U.S. with the passage of the Farm Bill.
But, if we’re being frank, all of this will pale in comparison to what’s coming in 2019.
In fact, we believe one sector alone will outshine everything we saw last year combined…
The Year of CBD
One year from now, 2019 will be remembered as “The Year of CBD.”
CBD, or cannabidiol, is the main non-psychoactive component of cannabis. It, along with other non-psychoactive compounds in cannabis, shows enormous promise for treating a variety of symptoms, including post-traumatic stress disorder, autism, schizophrenia, and more.
CBD is also rapidly gaining popularity as a general health treatment, with people taking it for everything from keeping energy up to arthritis. It’s even used as a pet health supplement. And the National Institute for Cannabis Investors isn’t alone in singing CBD’s virtues anymore – we’re starting to see recurring coverage in The New York Times and on talk shows.
And the passage of the Farm Bill effectively normalizes CBD across the country by making industrial hemp, a major source for CBD, legal on the federal level.
Hemp farmers can now access banking services, crop insurance, and even federal grants for research that were previously unavailable. For manufacturers and distributors, it is now clear that it is legal to transport hemp and its products, including CBD, across state lines. Moreover, retailers can now sell CBD without fear of enforcement action by the government.
And in March, the U.N. is set to deschedule CBD, whether sourced from marijuana or hemp, giving CBD products the green light throughout the free world.
All of these catalysts will combine to create a market unlike anything we’ve ever seen before.
CBD’s Journey to a $2 Billion Market
There is a large backlog of companies that have been itching to make or sell products from hemp, and some already-successful companies are poised to make massive profits from feeding the demand. The best of those companies has been in our Cannabis Investor’s Report portfolio since this service launched in October.
Within a few months, CBD will be available in a much larger variety of products. You will be able to choose among tinctures (currently the primary form of consumption), gummies, energy shots, nutrition bars, skin moisturizers, infused ingredients like honey, and more.
And with the rapidly increasing acceptance of cannabis and in CBD in particular – these products – old and new – will be available in everyday stores across the nation. As one executive of a mainstream retailer said, “We have seen recent shifts in consumer behavior accelerate changes in the retail industry. North America’s widespread adoption of the use of CBD products is one of the best examples of these shifts.”
We just brought together former Speaker of the House John Boehner and the most powerful people in the cannabis world – and they revealed an uncensored, highly controversial prediction that could help you make a fortune. If you missed seeing this historic event LIVE, click here for a special rebroadcast.
By the end of the year, people will be buying pallets of CBD products at Costco just as they purchase other health supplements, from eggs with additional Omega-3 added to supplements like protein powders.
Throughout this year, I predict demand for CBD products to at least triple to nearly $2 billion, but that number could increase as much as five times, to $3 billion – and our pick will be leading the way.
That’s because it is already the largest producer of CBD in the United States and it has the best reputation of any provider we’ve researched. It also has the most extensive network of farmers to provide all that CBD. Finally, based on the talent it is adding to its executive team, it has every intention of building a consumer packaged goods behemoth with global reach.
CBD Market Could Reach $20 Billion By 2024, Says New Study
Iris Dorbian
Contributor
Affecting industries as diverse as cosmetics, food and beverage and pharmaceuticals, the exploding CBD (cannabidiol) market has generated considerable headlines, providing fodder to umpteenth analysis and forecasts. The latest one, by leading cannabis researchers BDS Analytics and Arcview Market Research, projects that the collective market for CBD sales in the U.S. will surpass $20 billion by 2024. Interestingly, this figure is a slight increase from than the recent forecast made by New York-based investment bank Cowen & Co, which estimated that the market could pull in $15 billion by 2025.
The new forecast takes into account products sold through licensed dispensaries, pharmaceuticals and in general market retail, which includes cafes, smoke shops, grocery stores and pharmacies. However, BDS Analytics predicts that the majority of CBD product sales will soon occur in general retail stores instead of cannabis dispensaries. When you consider how cannabis has become increasingly integrated into mainstream society, as represented by the number of states that have legalized recreational or medical markets (33 and D.C for recreational use and 10 states plus D.C. for adult use), the BDS prognostication makes perfect sense.
But sales will continue from other distribution channels. In fact, BDS Analytics is predicting an compound annual growth rate of 49 percent by 2024 across all distribution channels. Also, they expect that the CBD market, combined with THC products, will create a total market of $45 billion for cannabinoids by 2014.
Other findings from the new study include:
CBD product sales in dispensaries since 2014 have grown at an even faster rate than overall sales in dispensaries;
66 percent of hemp-derived CBD consumers in the U.S. agree with full federal legalization of cannabis, with 90 percent believing that marijuana has medical benefits; and
CBD consumers are an average age of 40, have higher education, and are more likely than non-consumers to be employed full time.
Jessica Lukas, vice president of consumer insights at BDS Analytics, explained how the Boulder, Colorado-based firm cast this latest forecast. “We had to look at the landscape today, and then assess and predict where the market will go,” she said. “THC and CBD are very different with different functionality. Product forms that make sense and are very successful for THC do not necessarily transfer to CBD. Additionally, we had to strongly consider the interaction between the general market channels and the dispensary channel in assessing whether or not the availability of CBD products in the general market is incremental to purchases in dispensaries, will replace dispensary purchases, and/or will drive greater penetration and acceptance of legal cannabis.”
Estimating the size of the market by channel and category was a challenge in the data-gathering process. “Most products being sold in the general market today are in untracked channels of distribution,” said Lukas. Yet even with this problem, she is expecting many categories (food, candy, beverages, beauty, skin, etc.) will generate substantial volume across many channels of distribution. “While dispensaries and ecommerce drive the majority of cannabinoid sales today in the U.S, this shifts versus the next five years,” she added.
K.R. is setting this company up for -
an "OWC$ " -like run. ( OWC$ RAN FROM .003'S TO $ 3.25)
HOLD ONTO YOUR SHARES , FOLKS $$$$$
KARL RIEDEL had OVER 9,000 affiliates with -
his last venture. the man has ENDLESS CONNECTIONS! -
AND just watch what happens after the upcoming H.T.C.C.
GO PAOG !
I agree, L.T.-
K.R. knows how to bring in REVENUES- OVER $ 100 MILLION with
his last company. he's setting this company up just right.
just a matter of time before the pps takes off.
PAOG = HUGE $$$$$
"Detroit High Times Cannabis CUP" -
will only be the launching pad for PAOG-
expecting to see many new manufacturing and distribution contracts,
especially with all of KARL'S connections and affiliates.
NOT to mention- the exploding CBD INDUSTRY and CBD MANIA that's about
to hit us.
GO PAOG $$$$$
KARL RIEDEL-
" I personally generated $100M+ in revenue. Period."
you can bet KARL has the vision with PAOG, or he wouldn't have signed on
as CEO. the man has the connections to make PAOG a major player in the
CBD INDUSTRY.
keep patient and stay the course.
"Regarding PAOG, and my plans to dominate the Michigan cannabis market, I've done my best to give you all the roadmap for where we are headed.
I'm keeping alot of surprises up my sleeve regarding our MI cannabis company, because I'm excited to unveil the big surprise to shareholders. When the time is right. But I'm not letting the cat out of the bag yet. Stay tuned.
But when it comes to PAOG, and where I plan to take it, just remember...
I told you so. I'm assembling a team to accomplish these goals. You can believe in my vision, and understand that I have both a short-term and longterm strategy. Or don't. But THANK YOU to everyone who continues to support us. "
- Karl Riedel | CEO
just the facts, please-
KARL REIDEL-
CEO- PAOG -" He grew the largest affiliate program in the vapor industry with over 9000 affiliates worldwide, and was responsible for generating $100MM+ in revenue for the company".
PAOG IS NOW # 7 ON MOST ACTIVE I-HUB BOARDS-
finally starting to hit the radars ?
sure looks like it .
GO PAOG $$$$$
PAOG is primed and poised to take -
full advantage of the upcoming CBD MANIA about to hit in the coming
months. its going to be like SEPTEMBER 2016 . when OTC/BB MJ STOCKS ran
UP 1000 %%%%%
I was thinking the same thing- DOC-
he's making himself look ridiculous. take all kinds on this board.
K.R. pulled in OVER $ 100 MILLION DOLLARS IN REVENUES with his last company. who knows how much in revenues with PAOG ?
but i'm holding LONG AND STRONG to find out !
BRING ON THE H.T.C.C. !!!
PAOG $$$$$$$$
good luck, G.C.- but the price
is about to go up sharply. just watch the pps as we get closer
to the H.T.C.C. AND the FDA is about to announce some game-changing
rules and regs. on CBD.
nice pics., DOC- very professional-
and sharply packaged. KARL definitely knows what he's doing here, and it
shows. he's building this company to be a real "blockbuster".
BRING ON THE H.T.C.C. in DETROIT !!!!
just like someone on here posted-
K.R. knows the vaping industry. its his specialty, along with
bringing in HUGE REVENUES $$$
KARL RIEDEL IS THE $ 100 MILLION DOLLAR + MAN ! -
$ 100 MILLION +++ IN REVENUES-
KARL REIDEL-
CEO- PAOG -" He grew the largest affiliate program in the vapor industry with over 9000 affiliates worldwide, and was responsible for generating $100MM+ in revenue for the company".
"CBD MANIA " is coming and-
we're looking at a $ 24 BILLION DOLLAR INDUSTRY.
K.R. is positioning this company at just the right time !
exciting times ahead for PAOG SHAREHOLDERS $$$$
DOC- there's no doubt we have some serious increasing volume-
past 10 days we have averaged 5.6 mil. shares per day. the
previous 10 days, we averaged only 2.1 mil. shares.
that's an almost 170 % DAILY VOLUME INCREASE !
something BIG is brewing here .
PAOG $$$$$
and i'm seeing a lot of -
buying and holding going on with PAOG .
tick-tock- the clock is ticking until
KAAAABOOOOOOOOM TIME !
.03 in SEPTEMBER .
I gotta feeling we have much more coming from-
K.R. it will be interesting to see what else he has coming out-
"i'm keeping a lot of surprises up my sleeve "-
"Believe me, I read these boards intermittently, and I have a team of people monitoring for me. I've done my best to be 100% transparent with my plans for PAOG, and I'm all about the "underpromise and overdeliver" - I just believe in keeping our shareholders informed along the way. For those saying I don't have CEO experience and didn't do much for VMR and the acquisition, you need to understand that I was responsible for most of the revenue ever generated for VMR, since its inception. Where they spent the money, and how the company wound up in debt, was not my department. I personally generated $100M+ in revenue. Period.
Regarding PAOG, and my plans to dominate the Michigan cannabis market, I've done my best to give you all the roadmap for where we are headed.
I'm keeping alot of surprises up my sleeve regarding our MI cannabis company, because I'm excited to unveil the big surprise to shareholders. When the time is right. But I'm not letting the cat out of the bag yet. Stay tuned.
But when it comes to PAOG, and where I plan to take it, just remember...
I told you so. I'm assembling a team to accomplish these goals. You can believe in my vision, and understand that I have both a short-term and longterm strategy. Or don't. But THANK YOU to everyone who continues to support us. "
- Karl Riedel | CEO
DOC- have you noticed how -
KARL RIEDEL is coyly releasing and introducing new products?
the guy is a marketing genius, and has a recent history of OVER $ 100
MILLION in REVENUES to show for it.
GO PAOG $$$$$
the SMART MONEY" is accumulating -
big-time here. NOW is the time to BUY PAOG-
before the herds come stampeding in .
PAOG- BUY-ACCUMULATE- HOLD= HUGE $$$$$$$$$
"CBD, a non-psychoactive ingredient in cannabis, is widely believed to have wellness properties and the potential to treat a range of maladies, including chronic pain, inflammation and anxiety."
you guys better believe K.R. is keeping up with current FDA events, as any major decisions/changes that they make, will be in the interest of PAOG.
this is HUGE NEWS-
and will definitely have a big effect on PAOG'S business going forward.
when the FDA changes its stance on CBD, all bets will be off !
PAOG WILL SKYROCKET !
FDA Today https://us.eversheds-sutherland.com/NewsCommentary/Legal-Alerts/222726/Legal-Alert-After-pressure-from-the-US-Senate-the-FDA-signals-movement-on-CBD-regulations
PREPARE FOR THE BIGGEST UPCOMING "CBD MANIA" EVER !!!-
from " SLEEK "- the man who predicted the last GREAT OTC/BB MJ MANIA - and he made many,many people very wealthy on his MJ STOCK calls.
THE CBD MANIA IS COMING IN SUMMER/FALL 2019
The perfect storm is brewing for THC-Free Hemp-derived CBD to take center stage in America
Pushing everything forward — Congress, Big Food, Big Beverage, Big Alcohol, Hemp Industry, Hemp-CBD Investors, MJ Investors in America who realize that MJ under this Senate/DOJ is dead
Holding everything back — FDA (Nary a peep from GW and Big Pharma, just crickets chirping)
The Farmer’s Deadline — 2020 Planting Season — they need to figure out their planting plans by late 2019/early 2020
The Political Stakes — 2020 election
Mitch and Trump are on the chopping block and both need the farmers to vote for them in big numbers
FDA docket on CBD closes next week on July 16th
California on schedule to pass CBD in supplements and food in July/August
Senator Wyden’s request for FDA to announce formal policy of enforcement discretion by 8/1/19:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149611736
USDA Interim Regs are coming out in August
FDA Co-Chair of Internal Working Group on CBD Mr. Schiller speaks at National Hemp Conference on August 13th:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149883491
The demand for FDA Interim Regs is going to skyrocket the minute the USDA publishes their Interim Regs next month
FDA recommendations for interim framework/legislation coming in September:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149895241
The table is now set for the CBD Mania
Mitch met with the FDA Commissioner a few weeks ago to talk turkey:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149655173
Look for Mitch to bring up the prospect of Congressional Legislation on CBD in 2019 within the next few weeks
I am ready for the mania at any point moving forward and believe we will see it within the next 95 days or so
I know we’ve discussed a variety of different triggers, but it may wind up being something as simple as a Trump tweet that kicks off the mania
I’m ready if it hits next week or the week after, though I believe the Aug/Sept/Oct timeframe is when it is most likely to begin
Sleek
THESE ARE THE FACTS: - $ 100 MILLION +++ IN REVENUES-
KARL REIDEL-
CEO- PAOG -" He grew the largest affiliate program in the vapor industry with over 9000 affiliates worldwide, and was responsible for generating $100MM+ in revenue for the company.
"Regarding PAOG, and my plans to dominate the Michigan cannabis market, I've done my best to give you all the roadmap for where we are headed.
I'm keeping alot of surprises up my sleeve regarding our MI cannabis company, because I'm excited to unveil the big surprise to shareholders. When the time is right. But I'm not letting the cat out of the bag yet. Stay tuned.
But when it comes to PAOG, and where I plan to take it, just remember...
I told you so. I'm assembling a team to accomplish these goals. You can believe in my vision, and understand that I have both a short-term and longterm strategy. Or don't. But THANK YOU to everyone who continues to support us. "
- Karl Riedel | CEO
are we also going to-
OKLAHOMA ?